Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma skyrocketed by 281%. In 2024, Fierce Biotech reported 192 ...

Novo Nordisk, for its part, is expected to jump from 10th place to sixth this year, according to Evaluate Pharma’s consensus forecasts. Nevertheless, it’s Roche that’s been tipped to stand ...

What does that mean? If you’re an evidence-based thinker, it means nothing. If you’re a believer in astrology, however, it means I was born at a time of the year when the sun’s influence on ...

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...

This scenario indicates that 2025 will be a promising year for the pharma sector. A report by Axis Securities last month outlined a positive outlook for the pharmaceutical sector over the next three ...

As may be expected, the United States maintained its position as the leader in pharmaceutical innovation, contributing to nearly half of all drugs in development. However, China’s influence in global ...